Cefiderocol 1 g per vial Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 g per vial
Originator reference: Fetroja (USA), Fetcroja (EU/UK) (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Antibiotics
Cefiderocol is a siderophore cephalosporin antibiotic used to treat serious Gram-negative bacterial infections, including those caused by multidrug-resistant organisms. It works by binding to extracellular iron, using bacterial iron uptake systems to penetrate and inhibit cell wall synthesis. It is particularly effective against carbapenem-resistant strains such as Pseudomonas aeruginosa and Acinetobacter baumannii. Cefiderocol is available as a 1 g IV powder under the brand names Fetroja and Fetcroja.
Manufacture or export Cefiderocol? List it or send an offer →
Product Description:
Cefiderocol is a siderophore cephalosporin, and its mechanism is genuinely novel. Gram-negative bacteria actively scavenge iron from their environment using siderophores. Cefiderocol chelates ferric iron and is then transported into the periplasmic space through the bacterium's own iron uptake channels — a "Trojan horse" route that bypasses the porin loss and efflux pumps by which resistant organisms exclude conventional beta-lactams.
The result is activity against carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia, including metallo-beta-lactamase producers against which most other agents fail. It is indicated for complicated urinary tract infection and for hospital-acquired and ventilator-associated pneumonia caused by susceptible Gram-negative organisms, supplied as 1 g powder for injection.
Sourcing notes, and these are decisive. Cefiderocol is a patented innovator product from a single manufacturer. No generic has been approved anywhere, the underlying patents were filed in 2019, and realistic generic entry is more than a decade away. It cannot be sourced on a bulk or contract manufacturing basis, and an offer of generic cefiderocol should be refused and investigated. WHO classifies it under Reserve, the most restricted AWaRe category, meaning its use is confined to confirmed multidrug-resistant infection under stewardship control. Legitimate supply runs through authorised distribution, or through named-patient import where the product is not registered locally.
How Cefiderocol is supplied today, and licensing ahead of patent expiry
Frequently Asked Questions
Cefiderocol is used to treat serious bacterial infections caused by Gram-negative bacteria, including multidrug-resistant strains. It is indicated for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and infections due to carbapenem-resistant pathogens when no suitable alternatives are available.
Cefiderocol is made from the active ingredient cefiderocol, a siderophore cephalosporin antibiotic. It works by binding to iron and using bacterial iron transport systems to enter bacterial cells, where it inhibits cell wall synthesis, leading to bacterial death. Its chemical name is (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[2-(2,3-dihydroxybenzoyl)oxypropyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
The trade name of cefiderocol is Fetroja in the United States and Fetcroja in the European Union and United Kingdom.
Cefiderocol (Fetroja/Fetcroja) is manufactured and marketed by Shionogi & Co., Ltd., a Japanese pharmaceutical company.
The generic name of the drug is cefiderocol.
The brand names of cefiderocol are Fetroja (USA) and Fetcroja (EU/UK).
Cefiderocol is manufactured by Shionogi & Co., Ltd. in Japan and distributed globally through its subsidiaries and partners in the United States, the European Union, and other international markets.
Cefiderocol is sold as Fetroja and Fetcroja. It is developed and sold by Shionogi. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.
Related Products
Gatifloxacin
Strength:
0.3%
Form: Eye Drops
Originator reference: Zymar (USA), Zymaxid (USA)
View DetailsFidaxomicin
Strength:
200mg, 40mg/5ml
Form: Tablets / Oral suspension
Originator reference: Dificid (USA), Dificlir (EU/UK)
View DetailsDemeclocycline Hydrochloride
Strength:
150mg, 300mg
Form: Tablets
Originator reference: Declomycin (USA/EU)
View DetailsAzithromycin Tablet
Strength:
250 mg, 500 mg, 600 mg
Form: Tablet
Originator reference: Zithromax(US & EU)
View DetailsAmoxacillin Oral Capsules/Tablets
Strength:
250 mg, 500 mg, 875 mg, 1000 mg
Form: Oral Capsules/Tablets
Originator reference: Amoxil(US)
View DetailsAmoxicillin Powder for Suspension
Strength:
125 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL
Form: Powder for Suspension
Originator reference: US: Amoxil
View DetailsAmoxycillin / Potassium Clavulanate Tablets
Strength:
500 mg/125 mg, 875 mg/125 mg, 2 g/125 mg
Form: Tablets
Originator reference: Augmentin, Augmentin XR(US); Augmentin(EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit